Launched in 2023, the Sinocare iCan Continuous Glucose Monitoring System (CGMS) features accuracy, simplicity, and affordability as its core strengths. It is the world’s first CGM product to apply third-generation glucose sensing technology and possesses globally available proprietary intellectual property. The product employs specially treated enzymes and a unique electron transfer method, completely resolving oxygen interference and accuracy issues. As a result, the iCan I3 achieves a MARD of 8.71% with a monitoring duration of 15 days—the longest in the industry—while the iCan H3 achieves a MARD as low as 7.45%, reaching a world-leading level. In February 2025, the iCan i6 was officially released, featuring: easy to wear: no assembly required, simply press to attach; slim and compact: as light as thin paper, as small as a coin; accurate and stable: proprietary patents and enhanced craftsmanship ensure reliable performance.